4
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Identifying very low-risk STEMI patients for early ICU discharge in the COVID-19 era

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Sirs: Assessment of individual patient risk for short-term outcomes following acute ST-elevation myocardial infarction (STEMI) has focused on risk scores with high sensitivity to identify high-risk patients [1]. By contrast, there is a lack of uniformly accepted scores for predicting the absence of complications following primary percutaneous intervention (pPCI), and current guidelines still recommend admission in intensive care unit (ICU) during at least 24 h after symptoms onset in patients with uncomplicated STEMI [1–3]. Minimizing ICU admissions, particularly in the current COVID-19 era, is paramount for minimizing patient exposure and optimizing resource allocation [4–6]. We hypothesized whether in the era of regional pPCI reperfusion networks, uncomplicated STEMI patients remaining event-free following prompt TIMI 3 flow restoration, would facilitate early discharge from the ICU [7, 8]. The present study aimed to identify predictors of very low-risk STEMI patients following uncomplicated pPCI, and to assess the safety of an early ICU discharge strategy. To test our hypothesis, we analyzed consecutive STEMI patients undergoing pPCI in our referral area (~ 850,000 inhabitants) arriving within 12 h after symptom onset, between 2012 and 2019 (n = 2185). Per protocol all patients received a loading dose of 300 mg of aspirin plus 600 mg of clopidogrel or 180 mg of ticagrelor or 60 mg of prasugrel before the procedure. We recorded in a prospective dedicated database clinical characteristics, peri-procedural complications including arrhythmias, Killip-Kimball class, reperfusion time, and procedural characteristics; 24-h ICU cardiac complications including ventricular fibrillation/tachycardia, A-V block or asystole, acute pulmonary edema, mechanical ventilation, shock, acute stent thrombosis and cardiac death; and 30-day cardiac death. Patients were divided in two cohorts: a derivation cohort (n = 1492; years 2012–2016) to identify independent very low-risk predictors; and a validation cohort (n = 693; years 2017–2019). Univariate and multivariate logistic regression analysis were used to determine predictors of 24-h cardiac complications and 30-day cardiac death. Multivariate analysis included clinical and procedural predictors that exhibited a p value < 0.05 in the univariate analysis. First, multivariable-independent predictors allowed patient stratification in to very low-risk (odds ratio ≤ 0.85 for early cardiac complications and 30-day cardiac death) and other risk groups. Next, cardiac events beyond the first 6 h in the ICU were characterized in the very low-risk group. Finally, specificity to predict early cardiac complications and 30-day cardiac death in the very-low risk group was also assessed. Derivation cohort independent predictors of very low-risk were age ≤ 75 years-old, absence of primary malignant arrhythmias during the first assistance, Killip-Kimball class I, radial access, absence of left main or three-vessel coronary disease, and successful angioplasty-stenting (defined as final TIMI 3 flow), as shown in Table 1. The same very low-risk predictors emerged in the validation cohort (data not presented). Table 1 Univatiate and multivariate analysis of predictors of very low-risk of 24-h cardiac events and 30-day cardiac death following primary percutaneous coronary intervention Clinical and procedural predictors No complication (n = 1348) Complication (n = 144) p Early complication* [OR, 95% CI] p 30-day cardiac death [OR, 95% CI] p Age ≤ 75 year old 1074 (80) 88 (61) < 0.01 0.56 [0.37–0.84] < 0.01 0.10 [0.04–0.20] < 0.01 Female gender 296 (22) 41 (29) 010 Diabetes mellitus 328 (24) 44 (31) 0.12 Previous vascular disease (any) 274 (20) 43 (30) 0.01 Anterior myocardial infarction 546 (41) 75 (52) 0.01 Killip class I at presentation 1179 (88) 59 (41) < 0.01 0.14 [0.10–0.22] < 0.01 0.12 [0.06–0.26] < 0.01 No arrhythmia first assistance† 180 (13) 59 (41) < 0.01 0.32 [0.21–0.21] < 0.01 0.36 [0.17–0.76] < 0.01 Radial access 1320 (98) 125 (87) < 0.01 0.50 [0.24–1.04] 0.06 0.18 [0.07–0.46] < 0.01 No three vessel/LM disease 283 (21) 46 (32) < 0.01 0.85 [0.56–1.30] 0.40 0.51 [0.25–1.00] 0.05 Stent implanted 1321 (98) 144 (100) 0.20 Successful angioplasty-stenting‡ 1263 (94) 121 (84) < 0.01 0.42 [0.10–0.21] < 0.01 0.16 [0.07–0.37] < 0.01 Complete revascularization 519 (39) 46 (32) 0.16 Reperfusion time (minutes) 191 (130–309) 181 (129–299) 0.60 IIb/IIIa inhibitors use 547 (41) 50 (34) 0.36 Dual antiplatelet load 1348 (100) 144 (100) NA Baseline oral anticoagulation 44 (3) 12 (8) 0.02 ICU cardiac predictors**  LVEF < 40% 1166 (86) 77 (54) < 0.001 NA NA  Creatinin clearance (ml/min) 92 (42) 68 (38) < 0.001 NA NA Values presented as n (%) or mean (SD) or median (Q1–Q3) ICU intensive care unit, NA not assessed, LM left main, LVEF left ventricular ejection fraction *Including 24-h cardiac death, malignant arrhythmias, severe heart failure, stent thrombosis/re-acute myocardial infarction **Intensive Care Unit predictors were not included in the multivariate analysis †Including atrial or ventricular fibrillation, ventricular tachycardia, A-V block or asystole appeared until the end of primary percutaneous coronary intervention procedure ‡Defined as final TIMI 3 flow without major procedural complications In the derivation cohort, 144 of 1492 (9.7%) patients had a 24-h-cardiac event (21 patients with stent thrombosis); 50 (3.4%) suffered a 30-day cardiac death; and 638 (43%) met very-low risk criteria. In the very-low-risk group, seven patients (1.1%) had a 24-h-cardiac event, all due to stent thrombosis, one with concomitant ventricular fibrillation (specificity = 0.95, p < 0.01). No 30-day cardiac deaths were recorded in the very low-risk group (specificity = 1, p < 0.01). In the validation cohort, 78 of 693 (11.3%) patients had a 24-h-cardiac event (16 of them stent thrombosis); 17 (2.5%) suffered a 30-day cardiac death; and 369 (53%) met criteria of very-low risk. In the very-low risk group, ten patients (2.7%) had a 24-h-cardiac event, nine due to stent thrombosis, (one with concomitant ventricular fibrillation) and one due to heart failure (patient with active hemolytic anemia complicated with systemic inflammatory syndrome) (specificity = 0.88, p < 0.01). No 30-day cardiac deaths were recorded in the very low-risk group (specificity = 1, p < 0.01). The 6-h ICU cut-point analysis performed in the very-low risk group only revealed one stent thrombosis event beyond the 6 h (0.9 ‰), without other complications (specificity ≈ 1, p < 0.01). This is the first study to focus on predictors of very low-risk of complications following STEMI in the pPCI reperfusion era. We found that younger patients with uncomplicated STEMI without complex coronary anatomy are highly likely to remain uncomplicated providing the infarct related artery is successfully opened via transradial pPCI. Importantly, the identified variables may be easily recorded upon completion of the pPCI procedure. Proper identification of such very low-risk patients should improve current post-procedural decision-making algorithms, including very early (within 6 h) patient transfer from the intensive care to a conventional ward, thus optimizing intensive care resources for other life-threatening pathologies. Stent thrombosis is always concerning, and in this very-low risk stratification model, it was the least accurate event to predict; nevertheless, stent thrombosis usually manifests early post-pPCI. Indeed, only one patient presented stent thrombosis beyond 6 h after ICU admission. These data should be interpreted in the context of a regional pPCI reperfusion network that includes a high percentage of radial access and stenting, and short reperfusion delay [2]. Nevertheless, pending confirmation in larger prospective studies, an early discharge strategy from the ICU within 6 h post-successful pPCI may be a reasonably safe option in almost half of STEMI patients.

          Related collections

          Most cited references6

          • Record: found
          • Abstract: found
          • Article: found

          Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Prognostic assessment of patients with acute myocardial infarction treated with primary angioplasty: implications for early discharge.

            The aim of this study was to create a practical score for risk stratification in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary angioplasty and to assess the feasibility of early discharge in low-risk patients. A prognostic score was built according to 30-day mortality rates in 1791 patients undergoing primary angioplasty for STEMI. For the identified low-risk patients without any contraindication to early discharge, we estimated and compared the costs of conventional care (prolonged 24-hour hospitalization) with the costs of shifting the care from inpatient to outpatient setting (early discharge) between 48 and 72 hours. Independent predictors of 30-day mortality included in the score were age, anterior infarction, Killip class, ischemic time, postprocedural Thrombolysis In Myocardial Infarction (TIMI) flow, and multivessel disease. This score was able to identify a large cohort (73.4%) of low-risk (score < or =3) patients, with a good discriminatory capacity (c statistic=0.907). The mortality rate was 0.1% at 2 days and 0.2% between 2 and 10 days in patients with a score < or =3. The incremental cost-effectiveness ratio for late discharge in low-risk patients was estimated at 1949.33. Therefore, this policy would save 1 life per 1097 low-risk patients, at additional costs of 194 933.33, in comparison with an early discharge policy. This score is a practical and useful index for risk stratification after primary angioplasty for STEMI, with a significant impact on clinical decision-making and the related costs. It reliably identifies a large group of patients at very low risk, who may safely be discharged early after primary angioplasty.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation

              Coronavirus diseases 2019 (COVID-19) has become a worldwide pandemic affecting people at high risk and particularly at advanced age, cardiovascular and pulmonary disease. As cardiovascular patients are at high risk but also have dyspnea and fatigue as leading symptoms, prevention, diagnostics and treatment in these patients are important to provide adequate care for those with or without COVID-19 but most importantly when comorbid cardiovascular conditions are present. Severe COVID-19 with acute respiratory distress (ARDS) is challenging as patients with elevated myocardial markers such as troponin are at enhanced high risk for fatal outcomes. As angiotensin-converting enzyme 2 (ACE2) is regarded as the viral receptor for cell entry and as the Coronavirus is downregulating this enzyme, which provides cardiovascular and pulmonary protection, there is ongoing discussions on whether treatment with cardiovascular drugs, which upregulate the viral receptor ACE2 should be modified. As most of the COVID-19 patients have cardiovascular comorbidities like hypertension, diabetes, coronary artery disease and heart failure, which imposes a high risk on these patients, cardiovascular therapy should not be modified or even withdrawn. As cardiac injury is a common feature of COVID-19 associated ARDS and is linked with poor outcomes, swift diagnostic management and specialist care of cardiovascular patients in the area of COVID-19 is of particular importance and deserves special attention.
                Bookmark

                Author and article information

                Contributors
                oabduljawadaltisent@gmail.com
                Journal
                Clin Res Cardiol
                Clin Res Cardiol
                Clinical Research in Cardiology
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                1861-0684
                1861-0692
                13 July 2020
                : 1-3
                Affiliations
                [1 ]GRID grid.7080.f, Germans Trias I Pujol University Hospital, , Universitat Autònoma de Barcelona, ; Carretera de Canyet s/n, 08916 Badalona, Barcelona Spain
                [2 ]CIBERCV, Madrid, Spain
                [3 ]GRID grid.239578.2, ISNI 0000 0001 0675 4725, Cleveland Clinic, ; Cleveland, OH USA
                Article
                1702
                10.1007/s00392-020-01702-0
                7356109
                32661674
                edb7a6c5-4ad9-403c-9c64-a55c734cd941
                © Springer-Verlag GmbH Germany, part of Springer Nature 2020

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                : 1 June 2020
                : 30 June 2020
                Categories
                Letter to the Editors

                Cardiovascular Medicine
                stemi,primary percutaneous coronary intervention,covid-19
                Cardiovascular Medicine
                stemi, primary percutaneous coronary intervention, covid-19

                Comments

                Comment on this article